C. Michael Gibson

@CMichaelGibson

Interventional cardiologist / Cardiologist

Boston, United States of America

Latest contributions

CSL112 (Apolipoprotein A-I) infusions and cardiovascular outcomes in patients with acute myocardial infarction (ApoA-I event reducing in ischemic syndromes II (AEGIS-II) Trial): Primary trial results

06 Apr 2024

Luis Ortega-Paz interviews C. Michael Gibson about the AEGIS-II primary trial results which he presented at ACC.24 in Atlanta.

ApoA-I post-heart attack showed no reduction in 90-day death or heart attack risk. However, exploratory analysis hints at benefits at one year, suggesting potential for longer-term efficacy.

Author

C. Michael Gibson

Author

Luis Ortega-Paz